Antibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 15858-1-AP - Provider product page

- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#15858-1-AP, RRID:AB_2186354
- Product name
- SF3A1 antibody
- Antibody type
- Polyclonal
- Description
- SF3A1 antibody (Cat. #15858-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IHC, IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references The molecular axis hnRNPU/circKCNK2/EDC4/IL-11 aggravates osteolytic bone metastasis of RCC.
Hydroxysafflor yellow A alleviates ischemic myocardial injury by targeting SF3A1 to improve mitochondrial energy metabolism.
Adipocyte-specific Steap4 deficiency reduced thermogenesis and energy expenditure in mice.
Integrative identification of non-coding regulatory regions driving metastatic prostate cancer.
ZC3H14 facilitates backsplicing by binding to exon-intron boundary and 3' UTR.
Cancer-associated snaR-A noncoding RNA interacts with core splicing machinery and disrupts processing of mRNA subpopulations.
Integrative identification of non-coding regulatory regions driving metastatic prostate cancer.
LXR agonist inhibits inflammation through regulating MyD88 mRNA alternative splicing.
SF3B1 association with chromatin determines splicing outcomes.
Wang Y, Zhao D, Lu J, Hou N, Wu Q, Zhou S, Xu J, Xue W, Cui W, Zheng J, Wang F, Zhai W
Oncogene 2025 Sep;44(36):3310-3332
Oncogene 2025 Sep;44(36):3310-3332
Hydroxysafflor yellow A alleviates ischemic myocardial injury by targeting SF3A1 to improve mitochondrial energy metabolism.
Wang BK, Wang R, Zhuo FF, Wang JK, Huang YL, Tu PF, Zeng KW, Li J
European journal of pharmacology 2025 Sep 5;1002:177789
European journal of pharmacology 2025 Sep 5;1002:177789
Adipocyte-specific Steap4 deficiency reduced thermogenesis and energy expenditure in mice.
Wang H, Zhang L, Chen X, Hong L, Zhao J, Qian W, Pham LK, Willard B, Li X, Bulek K, Li X
iScience 2025 Feb 21;28(2):111903
iScience 2025 Feb 21;28(2):111903
Integrative identification of non-coding regulatory regions driving metastatic prostate cancer.
Woo BJ, Moussavi-Baygi R, Karner H, Karimzadeh M, Yousefi H, Lee S, Garcia K, Joshi T, Yin K, Navickas A, Gilbert LA, Wang B, Asgharian H, Feng FY, Goodarzi H
Cell reports 2024 Sep 24;43(9):114764
Cell reports 2024 Sep 24;43(9):114764
ZC3H14 facilitates backsplicing by binding to exon-intron boundary and 3' UTR.
Li Q, Yang G, Ren B, Liu X, Tang LQ, Shi Q, Shan G, Wang X
Molecular cell 2024 Nov 21;84(22):4314-4333.e9
Molecular cell 2024 Nov 21;84(22):4314-4333.e9
Cancer-associated snaR-A noncoding RNA interacts with core splicing machinery and disrupts processing of mRNA subpopulations.
Zhou S, Lizarazo S, Mouli L, Chorghade S, Cheng R, Rajendra KC, Kalsotra A, Van Bortle K
bioRxiv : the preprint server for biology 2024 Jul 3;
bioRxiv : the preprint server for biology 2024 Jul 3;
Integrative identification of non-coding regulatory regions driving metastatic prostate cancer.
Woo BJ, Moussavi-Baygi R, Karner H, Karimzadeh M, Garcia K, Joshi T, Yin K, Navickas A, Gilbert LA, Wang B, Asgharian H, Feng FY, Goodarzi H
bioRxiv : the preprint server for biology 2023 Jun 2;
bioRxiv : the preprint server for biology 2023 Jun 2;
LXR agonist inhibits inflammation through regulating MyD88 mRNA alternative splicing.
Li N, Li Y, Han X, Zhang J, Han J, Jiang X, Wang W, Xu Y, Xu Y, Fu Y, Si S
Frontiers in pharmacology 2022;13:973612
Frontiers in pharmacology 2022;13:973612
SF3B1 association with chromatin determines splicing outcomes.
Kfir N, Lev-Maor G, Glaich O, Alajem A, Datta A, Sze SK, Meshorer E, Ast G
Cell reports 2015 Apr 28;11(4):618-29
Cell reports 2015 Apr 28;11(4):618-29
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image

- Experimental details
- K-562 cells were subjected to SDS PAGE followed by western blot with 15858-1-AP(SF3A1 antibody) at dilution of 1:1000
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image

- Experimental details
- Immunofluorescent analysis of HepG2 cells, using SF3A1 antibody 15858-1-AP at 1:25 dilution and Rhodamine-labeled goat anti-rabbit IgG (red).
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image

- Experimental details
- Immunohistochemical of paraffin-embedded human breast cancer using 15858-1-AP(SF3A1 antibody) at dilution of 1:400 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image

- Experimental details
- Immunohistochemical of paraffin-embedded human breast cancer using 15858-1-AP(SF3A1 antibody) at dilution of 1:400 (under 40x lens)
- Sample type
- tissue